The new vector contains an mRNA stabilising sequence (WPRE) and a nuclear import sequence (cPPT) which generate up to five-fold higher virus titers and emGFP expression than previous versions
Invitrogen has announced the launch of two new vectors for RNAi research.
The Block-iT HiPerform Lentiviral PolII miR RNAi expression system with emerald green fluorescent protein (EmGFP) offers the expected ability to deliver to nondividing, primary, and hard-to-transfect cells with lentiviral technology coupled to multi-site technology for promoter flexibility making it ideal for difficult applications including in vivo RNAi.
The new vector contains an mRNA stabilising sequence (WPRE) and a nuclear import sequence (cPPT) which generate up to five-fold higher virus titers and emGFP expression than previous versions.
The Block-iT Inducible PolII miR RNAi expression system uses a tetracycline-inducible promoter that allows researchers to control miR RNAi expression so that even genes that are essential to the function of a cell may be knocked down.
